首页>
外国专利>
LOW-DOSE ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE
LOW-DOSE ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE
展开▼
机译：低剂量抗精神病药物，包括盐酸亚氨基替康盐酸盐
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: pharmaceuticals.;SUBSTANCE: group of inventions relates to chemical and pharmaceutical industry and represents methods for treating solid cancer, enhancing the antitumor effect in patients with solid cancers and a method for treating a patient with solid cancer received irinotecan hydrochloride hydrate, wherein the combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5, is administered to a patient with solid cancer in a dosage range of 35 to 70 mg/m2/day by the amount of trifluridine, and irinotecan hydrochloride hydrate is administered in a dosage range from 45 to 144 mg/m2/day. Invention is also a method for treating solid cancers, where the combination drug containing trifluridine and tyirycil hydrochloride in a molar ratio of 1:0.5 is administered in combination with irinotecan hydrochloride hydrate, where the dosage of the combination drug containing trifluridine and tyirycil hydrochloride in a molar ratio of 1:0.5 is 50 % to 100 % of the recommended dose in the monotherapy, and the dose of irinotecan hydrochloride hydrate is 25 % to 80 % of the recommended dose in the monotherapy.;EFFECT: group of inventions provides the enhanced antitumor effect of the combination drug, as well as the reduced side effects due to the use of relatively smaller amounts of active agents.;18 cl, 7 dwg, 3 tbl, 2 ex
展开▼
机译：领域：发明领域本发明涉及化学和制药工业，并且代表用于治疗实体癌，增强实体癌患者的抗肿瘤作用的方法和用于治疗接受伊立替康盐酸盐水合物的实体癌患者的方法，其中以摩尔比为1：0.5的比例将含有三氟吡啶和盐酸替拉西西的药物合剂以35至70 mg / m 2 /天的剂量施用于患有实体癌的患者，盐酸伊立替康水合物的给药剂量范围为45至144 mg / m 2 /天。本发明也是一种治疗实体癌的方法，其中将摩尔比为1：0.5的含有三氟吡啶和盐酸酪氨酸的组合药物与伊立替康盐酸盐水合物组合给药，其中将含有三氟吡啶和盐酸酪氨酸的组合药物的剂量1：0.5的摩尔比为单药治疗推荐剂量的50％至100％，盐酸伊立替康盐酸盐的剂量为单药治疗推荐剂量的25％至80％。组合药物的抗肿瘤作用，以及由于使用相对少量的活性剂而减少的副作用。; 18 cl，7 dwg，3 tbl，2 ex
展开▼
